References
- Callea M, Bellacchio E, Fattori F, et al. Acute myeloid leukemia in a 3 years old child with cleidocranial dysplasia. Leuk Lymphoma. 2015;57:2189–2191.
- Gardham A, Forsythe E, Goulden N. One in 10 million: a case of cleidocranial dysplasia and acute lymphoblastic leukaemia-more than just a coincidence? Clin Dysmorphol. 2012;21:170–171.
- Schnerch D, Lausch E, Becker H, et al. Up-regulation of RUNX2 in acute myeloid leukemia in a patient with an inherent RUNX2 haploinsufficiency and cleidocranial dysplasia. Leuk Lymphoma. 2014;55:1930–1932.
- van der Deen M, Taipaleenmäki H, Zhang Y, et al. MicroRNA-34c inversely couples the biological functions of the runt-related transcription factor RUNX2 and the tumor suppressor p53 in osteosarcoma. J Biol Chem. 2013;288:21307–21319.
- Blyth K, Cameron ER, Neil JC. The RUNX genes: gain or loss of function in cancer. Nat Rev Cancer. 2005;5:376–387.
- Osato M. Point mutations in the RUNX1/AML1 gene: another actor in RUNX leukemia. Oncogene. 2004;23:4284–4296.
- Zhou G, Chen Y, Zhou L, et al. CBFA1 mutation analysis and functional correlation with phenotypic variability in cleidocranial dysplasia. Hum Mol Genet. 1999;8:2311–2316.
- Quack I, Vonderstrass B, Stock M, et al. Mutation analysis of core binding factor A1 in patients with cleidocranial dysplasia. Am J Hum Genet. 1999;65:1268–1278.
- Song WJ, Sullivan MG, Legare RD, et al. Haploinsufficiency of CBFA2 causes familial thrombocytopenia with propensity to develop acute myelogenous leukaemia. Nat Genet. 1999;23:166–175.
- Gaidzik VI, Teleanu V, Papaemmanuil E, et al. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathological and genetic features. Leukemia. 2016;30:2282.
- Michaud J, Wu F, Osato M, et al. In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenic leukemia: implications for mechanisms of pathogenesis. Blood. 2002;99:1364–1372.
- Lu J, Maruyama M, Satake M, et al. Subcellular localization of the alpha and beta subunits of the acute myeloid leukemia-linked transcriptor factor PEBPβ/CBF. Mol Cell Biol. 1995;15:1651–1661.
- Tanaka Y, Watanabe T, Chiba N, et al. The protooncogene product, PEBP2beta/CBFbeta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures. Oncogene. 1997;15:677–683.
- Wang CQ, Chin DW, Chooi JY, et al. Cbfb deficiency results in differentiation blocks and stem/progenitor cell expansion in hematopoiesis. Leukemia. 2015;29:753–757.